496P - Alterations of cellular proliferation, apoptosis and autophagy by cucurbitacin B treatment in colon cancer cells

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Cancer Biology
Colon and Rectal Cancer
Basic Scientific Principles
Presenter Moltira Promkan
Citation Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533
Authors M. Promkan1, S. Dakeng2, P. Suebsakwong3, A. Suksamrarn3, P. Patmasiriwat4
  • 1Clinical Microscopy, Faculty of Medical Technology, Mahidol University, 73170 - Nakhon Pathom/TH
  • 2Clinical Microscopy, Faculty of Medical Technology, Mahidol University, 73170 - Nkhon Pathom/TH
  • 3Faculty Of Science, Ramkhamhaeng University, Bangkok/TH
  • 4Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Nkhon Pathom/TH



Cucurbitacin B, an oxygenated tetracyclic triterpenoid extracted from the Thai medicinal plant Trichosanthes cucumerina L., exhibited strong anti-proliferative effects against breast cancer cells. However, the molecular mechanism is not completely understood, especially in colon cancer. Colon or colorectal cancer is one of the most common and the leading causes of cancer-related deaths worldwide including in Thailand.


In this study, we explore the effect of cucurbitacin B on colon cancer cells. Caco-2 and SW620 were treated with the cucurbitacin B and determined for the inhibitory effects on the cell proliferation, transwell cell migration and invasion assay and also effected on colony formation. We examine the influence of cucurbitacin B on apoptosis and autophagy in colon cancer cells.


Upon cucurbitacin B treatment, we found it obvious that cucurbitacin B inhibited cellular proliferation, migration, invasion and colony formation by using anchorage independent growth. The result of flow cytometry also showed that cucurbitacin B can induce apoptosis and autophagy.


Our findings suggest that cucurbitacin B is effectively inhibiting colon cancer, Caco-2 and SW620 cells. However, these findings are now under further investigation in other cell types and/or other mechanisms that may contribute to the development of cucurbitacin B to anti-colon cancer agents. This submitted work provides another crucial progression in the result of cucurbitacin B in colon cancer cells. It may lead to the future application of cucurbitacin B for colon cancer therapy.

Clinical trial identification


All authors have declared no conflicts of interest.